Next Article in Journal
Engineered Recombinant Single Chain Variable Fragment of Monoclonal Antibody Provides Protection to Chickens Infected with H9N2 Avian Influenza
Next Article in Special Issue
Safety of Administering Live Vaccines during Pregnancy: A Systematic Review and Meta-Analysis of Pregnancy Outcomes
Previous Article in Journal
Vaccination Against Amyloidogenic Aggregates in Pancreatic Islets Prevents Development of Type 2 Diabetes Mellitus
Previous Article in Special Issue
Will We Have a Cohort of Healthcare Workers Full Vaccinated against Measles, Mumps, and Rubella?
Open AccessArticle

Trends of Adverse Events Following Immunization (AEFI) Reports of Human Papillomavirus Vaccine in the Valencian Community—Spain (2008–2018)

1
Hospital General Universitario de Alicante, Unit of Clinical Pharmacology, 03010 Alicante, Spain
2
Department of Community Nursing, Preventive Medicine and Public Health and History of Science, University of Alicante, San Vicente del Raspeig, 03690 Alicante, Spain
3
Centro de Farmacovigilancia de la Comunidad Valenciana, Dirección General de Farmacia y Productos Sanitarios, Conselleria de Sanitat Universal i Salut Pública, 46010 Valencia, Spain
4
Hospital Universitario del Vinalopó, Elche, 03293 Alicante, Spain
5
Dirección General de Salud Pública y Adicciones. Conselleria de Sanitat Universal i Salut Pública, 46021 Valencia, Spain
*
Author to whom correspondence should be addressed.
Vaccines 2020, 8(1), 117; https://doi.org/10.3390/vaccines8010117
Received: 13 February 2020 / Revised: 26 February 2020 / Accepted: 28 February 2020 / Published: 2 March 2020
Vaccine safety surveillance is essential in vaccination programs. We accomplished a descriptive study of surveillance AEFI-reporting rate in human papillomavirus (HPV) vaccine administered in the Valencian Community, Spain. Data were obtained from Spanish Pharmacovigilance Adverse Reactions Data (FEDRA). Reporting rates were calculated using local net doses distributed as the denominator. Trends were assessed using joinpoint regression with annual percent change (APC) reported. The AEFI-reports decreased between 2008 and 2018 in two periods, a fast decreasing rate from 2009 to 2011 (from 192.2 to 24.93 per 100000 doses; APC, −54.9%; 95%CI [−75.2; −17.7]), followed by a stable trend (−13% APC, 95%CI [−26.1; 2.4]). For the age group analysis, only the group aged 14–15 years old followed the same trend with -58.4% (95%CI [−73.9; −33.8]) APC during 2008–2011, and −8.8% (95%CI [−27.7; 15]) APC during 2011-2018. The majority of the reports (73.82%) were nonserious, involving reactions at or near the vaccination site, headache, and dizziness events. No death was reported. AEFI-reporting rates for HPV immunization in the Valencian Community have decreased considerably with two trend periods observed for girls aged 14–15 years old. Currently, the AEFI reporting rate shows a decreasing trend, perhaps following the Weber effect, and it could also be affected by media attention and coverage. View Full-Text
Keywords: adverse events following immunization (AEFIs); Human Papillomavirus vaccines; Spanish Pharmacovigilance System; vaccine safety; postlicensure surveillance adverse events following immunization (AEFIs); Human Papillomavirus vaccines; Spanish Pharmacovigilance System; vaccine safety; postlicensure surveillance
Show Figures

Figure 1

MDPI and ACS Style

Egoavil, C.M.; Tuells, J.; Carreras, J.J.; Montagud, E.; Pastor-Villalba, E.; Caballero, P.; Nolasco, A. Trends of Adverse Events Following Immunization (AEFI) Reports of Human Papillomavirus Vaccine in the Valencian Community—Spain (2008–2018). Vaccines 2020, 8, 117.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop